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ABSTRACT 
Bacteriophages (phages) or bacterial viruses have long been proposed as an alternative 
therapy against antibiotic resistant bacteria such as E. coli. Even though poorly documented 
in the scientific literature, a long clinical history of phage therapy in countries such as Russia 
and Georgia suggests potential value in the use of phages as antibacterial agents. E. coli is 
responsible for a wide range of diseases, intestinal (diarrhoea) and extra-intestinal (UTI, 
septicaemia, pneumoniae, meningitis), making it an ideal target for phage therapy. This 
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 review discusses the latest research focusing on the potential of phage therapy to tackle E. 
coli related illnesses. No intact phages are approved in EU or USA for human therapeutic 
use, but many successful in vitro and in vivo studies have been reported. However, additional 
research focused on in vivo multi-species models and human trials are required if phage 
therapy targeting E. coli pathotypes can be a story with happy end. 
INTRODUCTION 
Bacteriophage (phage) therapy describes the therapeutic use of bacterial viruses to treat 
bacterial infections. The story of phage therapy first began over a hundred years ago when 
bacteriologists such as Hankin, Gamaleya, Twort and d’Herelle (Keen 2015) each made 
separate observations of anti-bacterial activities now believed to associated with viruses. A 
century later, the literature is still populated with articles detailing the promise of phage 
therapy either as an alternative to antibiotic therapy or for use in patients for whom drug 
treatments have already failed. A long history of apparently successful bacteriophage therapy 
for humans has been reported in Eastern Europe (ELIAVA Institute in Tbilisi, Georgia; 
Russia), but the studies are often insufficiently documented, preventing their rigorous 
evaluation (Sulakvelidze, Alavidze and Morris 2001).  If we are to generate success stories in 
phage therapy, we must first understand the potential benefits and challenges associated with 
the field. For this review, we focus on phage therapy directed towards one of the one of the 
most common bacteria known to medicine, Escherichia coli. 
E. coli is a Gram-negative bacterium of many diverse types, the majority of which are part of 
the normal flora of the intestine and are believed to be relatively harmless. However, some 
strains have evolved mechanisms of pathogenicity, meaning they can cause disease in 
humans and animals. Such diseases can be intestinal (diarrhoea) or extra-intestinal, (urinary 
tract infection, septicaemia, pneumonia and meningitis) (Cabal et al. 2016; Millar et al. 
2016). Based on pathogenicity profiles (virulence factors, clinical disease and phylogenetic 
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 profile), E. coli causing intestinal disease have been divided into six pathotypes: 
Enteropathogenic E. coli (EPEC), Enterohaemorrhagic E. coli (EHEC), Enteroinvasive E. 
coli (EIEC, including Shigella sp), Enteroaggregative E. coli (EAEC), Enterotoxigenic E. coli 
(ETEC) and Diffusely Adherent E. coli (DAEC). Two further pathotypes have also recently 
emerged, the Adherent Invasive E. coli (AIEC), often associated with inflammatory bowel 
disease (IBD) disease, and the Shiga toxin (Stx)-producing Enteroaggregative E. coli 
(STEAEC) (Mora et al. 2011; Agus et al. 2014; Conte et al. 2014). Extra-intestinal E. coli are 
separated into groups determined by disease association, including uropathogenic E. coli 
(UPEC), neonatal meningitis-associated E. coli (NMEC), and sepsis-causing E. coli (SEPEC) 
(Clements et al. 2012).  
Current antibiotic treatments used to treat drug-resistant or/and adherent-invasive E. coli can 
result in severe alterations to an individual’s microbiota as well as continuous relapses of 
disease (Langdon, Crook and Dantas 2016). As an alternative to antibiotics, phages have 
regained increasing attention. Therapeutic approaches typically use individual phages or 
cocktail of phages to specifically infect and kill target bacteria. Because of their limited 
species-specific host range, bacteriophages have the potential to impact pathogenic bacteria 
without causing collateral damage to commensal microbiota (Brüssow 2005; Tomat et al. 
2013; Niu et al. 2014; Khan Mirzaei and Nilsson 2015). While the potential of phage therapy 
cannot be denied, the emergence of phage-resistant bacteria cannot be overlooked 
(Sulakvelidze, Alavidze and Morris 2001). An approach using a “phage cocktail” of multiple 
phage types with different host range specificities can help to alleviate potential problems 
with phage resistant ‘mutants’ (Dalmasso et al. 2015; Chadha, Katare and Chhibber 2016; 
Melo et al. 2016). Different mathematical models provide information on the maximum 
therapeutic effect of a phage population and quantitatively examine mutation rates of phage 
resistant bacteria (Kysela and Turner 2007; Beke, Stano and Klucar 2016). But phages can 
 by guest on N
ovem
ber 16, 2016
http://fem
sle.oxfordjournals.org/
D
ow
nloaded from
 
 also mutate, such that they then successfully eliminate the bacterium that acquired resistance 
in the first place, conferring a potential advantage to phage therapy over antibiotic treatment 
(Dufour et al. 2015).  
E. coli phages (coliphages) are commonly isolated from sewage, hospital waste water, 
polluted rivers and faecal samples of humans or animals (Song et al. 2007; Jamalludeen et al. 
2009; Walker, Clokie and Kropinski 2009; Dalmasso et al. 2016; Snyder, Perry and Yousef 
2016). Reports on phage therapy targeting various pathogenic E. coli have been described in 
the literature (Dufour et al. 2015, 2016; Sarker et al. 2015) and this review presents some of 
the recent findings of trials specifically targeting ExPEC, intestinal AIEC and EHEC. 
 
BACTERIOPHAGE TARGETING EXTRA-INTESTINAL PATHOGENIC 
ESCHERICHIA COLI (EXPEC) 
Extra-intestinal pathogenic E. coli (ExPEC) causes a diverse range of clinical diseases 
(bacteraemia, meningitis, urinary tract infections), and global morbidity and mortality rates 
due to ExPEC infections are on the rise.  
Extra-intestinal uropathogenic E. coli (UPEC) is the leading cause of urinary tract infections 
(UTIs), and is responsible for approximately 75% of cases of over 150 million clinical cases 
reported annually (Kakkanat et al. 2015). The highest prevalence is in females, with 40-50% 
developing a UTI in their lifetime, compared to only 5% of males. UTIs are usually managed 
with antibiotic therapy, but over the years, antibiotic-resistant strains UPEC have emerged. 
The formation of biofilms further complicates treatment options (Chibeu et al. 2012; Soto 
2014), encouraging more research into phage therapy against UPEC’s.  
Perepanova et al. (1994) described the efficiency of both local and oral administration of a 
multi-species bacteriophage cocktail to treat patients with acute and chronic urogenital 
inflammation, but the study is poorly documented for use as a model for human phage 
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 therapy. Chibeu et al. (2012) recently assessed the ability of three phages to eradicate UPEC 
biofilms and in 2016, Sybesma et al.  described the lytic activity of commercial 
bacteriophage cocktails on E. coli and Klebsiella pneumoniae strains isolated from UTI 
patients. They also demonstrated the potential of ‘bacteriophage adaptation’ experiments to 
increase the lytic activity of bacteriophage cocktails. Also in 2016, Galtier et al. isolated three 
virulent phages from wastewater that target an antibiotic resistant strain of UPEC. Phage 
efficacy was characterised both in vitro and in vivo, and it was found that a single dose of the 
three-phage cocktail was able to dramatically reduce gut carriage of UPEC. These studies are 
among many that hold promise for the potential of bacteriophage therapy for the treatment of 
E. coli acquired UTI’s.  
The UPEC pathotype E. coli ST131-025b:H4 has been identified as a pandemic strain with 
potential worldwide spread and serious implications as a nosocomial infection, which has 
been recorded in cystitis as well in life-threating meningitis. Part of the B2 phylogenetic 
group, E. coli ST131-025b:H4 has a large number of virulence factors which are also linked 
to high levels of resistance to β-lactams and fluoroquinolones. The plasmid-mediated colitis 
resistant gene (mcr-1) has also been recently associated with ST131(Hasman et al. 2015). 
Pouillot et al. (2012) first reported phage therapy against a ciprofloxacin resistant clone of 
ST131-025b:H4 (designated E. coli S242) isolated from a neonate with fatal meningitis. A 
phage (EC200
PP
) was isolated from sewage water from France, and which belongs to the 
Podoviridae family of phages, was able to treat sepsis and meningitis infections induced by 
drug-resistant E. coli.  In vivo activity of phage EC200
PP
 was not hampered by phage-
resistant mutants of E. coli S242. Pharmacokinetic studies of phage EC200
PP
 also showed it 
to be stable in urine. 
Dufour and his colleagues (2016) provided evidence of the efficiency of bacteriophage 
LM33-P1, that exclusively infects O25b E. coli strains, which are highly resistant to 
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 betalactams and fluoroquinolones. Bacteriophage LM33-P1 is very efficient in vitro (short 
eclipse and latent periods of 7 and 9 minutes respectively, burst size 320 pfu, fast adsorption) 
and also in vivo, based on different animal models (pneumonia, septicaemia and UTI). 
Dufour et al. (2016) also showed that the mutually exclusive and specific interaction of phage 
LM33-P1 with O25b strains was lipopolysaccharide (LPS)-dependent.  
 ExPECs have been associated with ventilator-associated pneumonia (VAP), a common life-
threatening hospital-acquired infection (Messika et al. 2012). The most predominant 
phylogenetic group is B2, with strains possessing a large number of virulence factor genes 
such as sfa and iroN that are essential for adhesion and iron uptake (Messika et al. 2012; 
Dufour et al. 2015). The use of bacteriophage to treat VAP offers an interesting alternative to 
conventional antibiotic therapies (Lynch, Clark and Zhanel 2013). In 2015, Doufour’s team 
published the first study on the efficient treatment of E. coli-induced pneumonia with two 
bacteriophages (536_P1 and 536_P7) isolated from sewage. They showed that a combination 
of antibiotic treatment and phage therapy resulted in a 100% survival rate in VAP infected 
mice. The majority of mice were not rescued by treatment with phage 536_P7 alone, but 
adaptation of this phage toward the VAP-causing E. coli strain resulted in a variant which 
significantly improved treatment efficacy in vivo. The study of Cao et al. (2015) supported 
the efficacy of bacteriophage treatment of pneumonia caused by multi-drug resistant K. 
pneumoniae. The lytic phage, KLPN1, was shown to infect and lyse capsular type K2 strains, 
and genome sequence analysis revealed the phage to encode proteins (e.g. lysins, holins) that 
have potential applications in phage-associated therapies. 
 
BACTERIOPHAGE TARGETING ADHERENT INVASIVE E. COLI (AIEC)  
Bacteriophage therapy targeting adherent invasive E. coli (AIEC), long suggested as an 
etiological agent of Crohn’s disease (CD), is gaining much academic and commercial interest 
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 as a therapeutic approach for the treatment of inflammatory bowel disease (IBD). While the 
role of AIEC in IBD is still subject to controversy, it does seem to have a higher prevalence 
in patients with IBD, as determined from faecal and biopsy samples (Glasser et al. 2001; 
Conte et al. 2014; da Silva Santos et al. 2015; O’Brien et al. 2016). It adheres to the ileal 
epithelium, invades the lamina propria and then proliferates within macrophages. While 
AIEC is a candidate target for antibiotic treatment of patients with Crohn’s Disease, the 
downside is that antibiotics may also target the beneficial microflora of the gut. While 
examples of phage therapy targeting IBD are sparse, it is interesting that bacteriophages, 
especially those from Caudovirales family, have been identified in a higher abundance in gut 
and ileal biopsies of CD patients (Jin, Zhang and Sun 2014), perhaps providing a potential 
basis for improvements in IBD diagnoses. Danglas and Debarbieux (2014) described eight 
different phages isolated from sewage which infect AIEC strain LF82, which is the reference 
strain for IBD studies. In a murine model with a derivative of LF82 engineered to have 
resistance to streptomycin and kanamycin (LF82KS), the levels of LF82(KS) recovered from 
stool were significantly lower when a cocktail of the eight phages was introduced. In 2014, 
Tsui, Jacobs and Braun.set out to prove the specificity of five AIEC phages, with the finding 
that each of the phages effectively targeted both non-adherent and adherent E. coli. When a 
combination of the phages was tested, it did not prove to be any more effective than the most 
potent of the phages alone, and the researchers are currently aiming to find AIEC mutants 
that have acquired resistance to the phages.  
Whilst preliminary data are promising for the place of phage therapy in IBD, one of the major 
outstanding issues is to specifically identify the correct target. In addition to AIEC, over-
represented bacteria in IBD have included Mycobacterium avium ssp. paratuberculosis, 
Clostridium difficile, Campylobacter concisus, Salmonella spp. and Enterococcus spp. 
Furthermore, the development of appropriate pre-clinical models for phage therapy studies 
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 relating to IBD are challenging because in many cases there is a difficulty in achieving 
efficient colonisation of the model with the test bacterium (Macfarlane, Steed and Macfarlane 
2009; Jin, Zhang and Sun 2014; Naser et al. 2014; Dulai et al. 2015; Zhang 2015). Multi-
species mouse models are therefore recommended for advancing phage therapy utilisation in 
IBD (Sartor and Mazmanian 2012; Eun et al. 2014). 
 
BACTERIOPHAGES TARGETING THE ENTEROHEMORRHAGIC 
PATHOTYPE OF E. COLI (EHEC) 
Intestinal pathogenic E. coli are generally divided into those that cause diarrhoea by 
expressing heat-labile or heat-stable toxin (enterotoxigenic E. coli (ETEC)) or Shiga toxin 
(Shiga toxin-producing E. coli (STEAEC), including enterohemorrhagic E. coli (EHEC). The 
most common EHEC, E. coli O157:H7, is usually community-acquired via contaminated 
food or water end is well known as a causative agent of diarrhoea and urinary problems 
(haemolytic uremic syndrome) in humans. It is evident that phage treatment of O157:H7 is 
not without its challenges, with only a modest 10-fold reduction in O157:H7 reported, even 
when phages were applied at a high multiplicity of infection (Sheng et al. 2006). In a separate 
trial, Sarker and team (2015) found that the oral application of phages to children hospitalised 
with acute diarrhoea failed to improve the diarrhoeal outcome, possibly due to insufficient 
ability of the phages to target the wide range of E. coli genetically variance. In addition, it 
was not clear whether E. coli was in fact responsible for the diarrhoea, as stool samples were 
largely dominated by faecal streptococci. Reduced effectiveness of phage titres following 
passage through gastric acid was identified as another possible reason for the trial failure. 
Furthermore, possible differences between physiological state of E. coli in faeces and in the 
intestine, and a low faecal titre of the pathogen, may not have allowed the replication of E. 
coli phages. These results confirm that far more knowledge is needed on in vivo phage-
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 bacterium interactions if we are to design effective phage therapy trials. On a positive note, 
the coliphages administered during the trial were found to safely transit the gut, helping to 
demonstrate the safety aspects of phage therapy.  
 
 
CONCLUSIONS  
Future studies focusing on phage therapy should answer the following questions: Is phage 
therapy efficient in vivo against a pathogen as complex as E. coli, with its high versatility and 
ability to change rapidly in time and space? Or should the concept of phage therapy against 
E. coli be consigned to history?  Despite some of the challenges presented, the data is still 
compelling for future applications of E. coli phage therapy, based on successful in vitro and 
pre-clinical in vivo demonstrations. However, we need robust data from more human clinical 
trials to fully assist development of phage therapy against the various E. coli pathotypes 
described.  
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